Search
Paclitaxel Treatment Options
A collection of 2016 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1009 - 1020 of 2016
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
Completed
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Gender:
ALL
Ages:
All
Trial Updated:
01/05/2021
Locations: Phoenix Children's Hospital, Phoenix, Arizona +4 locations
Conditions: CNS Germ Cell Tumor
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Completed
This is a non-randomized phase 1 trial designed to determine the MTD and evaluate the safety and tolerability of ACY-1215 with nab-paclitaxel. Based on the activity profile of ACY-1215 in breast cancer, corresponding biomarker availability with the HDAC6 MR score, and its potential synergy with taxanes, these data support the rationale for testing the ability of ACY-1215 to improve the response rate for patients with metastatic breast cancer in combination with standard taxane chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2021
Locations: Columbia Irving University Medical Center, New York, New York
Conditions: Metastatic Breast Cancer, Breast Carcinoma
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Completed
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2021
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Completed
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination with Abraxane (Abraxane) in Patients with Metastatic Breast Cancer (MBC) \[Phase I and II\]
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2020
Locations: Clinical Trials Research Unit, West Virginia University, Morgantown, West Virginia
Conditions: Metastatic Breast Cancer
Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Completed
The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this regimen. This combination of drugs is not a standard therapy for patients with squamous cell lung cancers. However, each of these drugs, when given alone or with o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2020
Locations: Miami Cancer Institute Baptist Health South Florida, Miami, Florida +5 locations
Conditions: Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of South Alabama/Mitchell Cancer Institute, Mobile, Alabama +248 locations
Conditions: Non-Small Cell Lung Cancer
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Completed
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of Chicago Medical Center Dept of Onc, Chicago, Illinois +12 locations
Conditions: Esophageal Squamous Cell Carcinoma
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Completed
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Novartis Investigative Site, Mobile, Alabama +6 locations
Conditions: HER-2 Positive Breast Cancer, Metastatic Breast Cancer
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Completed
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/16/2020
Locations: Dana Farber Cancer Institute SC, Boston, Massachusetts +6 locations
Conditions: Solid Tumors
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Completed
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2020
Locations: Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama +85 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Completed
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2020
Locations: Highlands Oncology Group, Fayetteville, Arkansas +4 locations
Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Fountain Valley, California +28 locations
Conditions: Non-small Cell Lung Cancer
1009 - 1020 of 2016